*December 2020*
Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in consideration of the heterogeneity of MET-amplified tumors.
METex14, METamp GCN≥10, and METamp GCN<10 represent subgroups of MET-dysregulated NSCLC with distinct molecular and clinical features. METex14 patients do not seem to benefit from immunotherapy in contrast to METamp patients, which is of particular relevance for the prognostically poor METamp GCN≥10 subgroup. Read more.
